Please use this identifier to cite or link to this item: http://nopr.niscair.res.in/handle/123456789/43082
Full metadata record
DC FieldValueLanguage
dc.contributor.authorAl-Najjar, Belal O-
dc.contributor.authorShakya, Ashok K-
dc.contributor.authorSaqallah, Fadi G-
dc.contributor.authorSaid, Rana-
dc.date.accessioned2017-11-13T08:57:49Z-
dc.date.available2017-11-13T08:57:49Z-
dc.date.issued2017-11-
dc.identifier.issn0975-0983(Online); 0376-4699(Print)-
dc.identifier.urihttp://nopr.niscair.res.in/handle/123456789/43082-
dc.description1200-1206en_US
dc.description.abstract15-Hydroxyprostaglandin dehydrogenase (15-PGDH) plays an important role in gastric ulcer healing, bone formation and dermal wound healing, encouraging several efforts to discover and optimize new inhibitors. We explored possible pharmacophoric space of 15-PGDH using four diverse sets of inhibitors. After that, GA and MLR methods have been employed to identify the optimal pharmacophore model(s) and physicochemical descriptors able to access Quantitative structure-activity relationship equation (r2=0.711, r2(adj)=0.6927, r2(LOO)= 0.6598). One pharmcophore model has emerged in the Quantitative structure-activity relationship equation and has been validated by ROC curve analysis and molecular docking.en_US
dc.language.isoen_USen_US
dc.publisherNISCAIR-CSIR, Indiaen_US
dc.rights CC Attribution-Noncommercial-No Derivative Works 2.5 Indiaen_US
dc.sourceIJC-B Vol.56B(11) [November 2017]en_US
dc.subject15-PGDHen_US
dc.subjectPharmacophore modelingen_US
dc.subjectQuantitative structure-activity relationshipen_US
dc.subjectDockingen_US
dc.titlePharmacophore modeling and 3D-QSAR studies of 15-hydroxyprostaglandin dehydrogenase (15-PGDH) inhibitorsen_US
dc.typeArticleen_US
Appears in Collections:IJC-B Vol.56B(11) [November 2017]

Files in This Item:
File Description SizeFormat 
IJCB 56B(11) 1200-1206.pdf560.86 kBAdobe PDFView/Open
IJCB 56B(11) 1200-1206_Suppl Data.pdf115.7 kBAdobe PDFView/Open


Items in NOPR are protected by copyright, with all rights reserved, unless otherwise indicated.